PRAME and acute myeloid leukemia: Reductions in PRAME mRNA levels in four of six r/rAML patients in cohorts 2 and 3, and the occurrence of CRS in two AML patients, indicated biological activity of MDG1011 applied at the two higher dose levels in patients with advanced r/rAML.